Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)

atrickpay

atrickpay
5 Followers
4 Following
Send Message
View as an RSS Feed
View atrickpay's Comments BY TICKER:
Latest  |  Highest rated
  • These 2 Patents Could Mean Everything Or Nothing [View article]
    quoth: how did you get this article approved so quickly and published? i know some people where they submit an article and it takes several days. Did some guy at s.a. just want this one publish really quickly?
    May 22 12:06 PM | 1 Like Like |Link to Comment
  • But, But BlackBerry Was Dead [View article]
    what is the source of the 6% and 13.5% figures? No sources given lol. Even at the source article for this, doesn't give the source of these q4 and q1's lol.
    May 17 03:16 PM | 1 Like Like |Link to Comment
  • Emerging Biomarker Companies Redux: Positioned For Growth [View article]
    Before the financing last week, VRML has 15.2m shares o/s. Using a s.p. of $1.46 gave it a cap of $22.19m. It's current cap of $91.03m divided by $22.19m is a 4.10x increase. In one week (!).
    May 15 03:49 PM | 0 Likes Like |Link to Comment
  • Emerging Biomarker Companies Redux: Positioned For Growth [View article]
    VRml has 15.2m shares o/s + 20.5m from the financing...so 35.7m in total...so it's worth $91.03m at $2.55/share
    May 15 03:45 PM | 0 Likes Like |Link to Comment
  • Emerging Biomarker Companies Redux: Positioned For Growth [View article]
    your mcap for vrml is wrong btw...
    May 15 03:44 PM | 0 Likes Like |Link to Comment
  • Emerging Biomarker Companies Redux: Positioned For Growth [View article]
    bgmd ipo'ed at 200$M? how many shares did the ipo consist of? it's now worth 46m$ per ihub..lost 75% of it's valuation lol for the ipo buyers
    May 15 03:41 PM | 0 Likes Like |Link to Comment
  • Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Propel Insmed [View article]
    Don't see 1 mention of the company's market cap in your article lol
    May 14 01:22 PM | 0 Likes Like |Link to Comment
  • Looking For Opportunity - 5 Biotechs That Crashed [View article]
    Depends on what their earnings #'s are (and if they can get profitable). If not, market cap on company mite not increase, and mite decrease further
    May 6 01:32 PM | 0 Likes Like |Link to Comment
  • Looking For Opportunity - 5 Biotechs That Crashed [View article]
    "It seems like little can pull this stock up from sinking further down". Nonsense, they need to start increasing their revenues on their quarterly reports
    May 6 01:31 PM | 0 Likes Like |Link to Comment
  • InspireMD: Moving Foward In Cardiac Stent Innovation [View article]
    was 1 insider sell in april..but the shares in the transaction were purchased by another insider : http://bit.ly/15kqgdT. So not bearish
    May 6 10:43 AM | 0 Likes Like |Link to Comment
  • MELA Sciences' CEO Discusses Q1 2013 Results - Earnings Call Transcript [View article]
    typo: "Cutting to the chase, the fourth quarter was our best to-date with recognized revenues of $144,000"...that should read first quarter
    May 1 02:37 PM | 0 Likes Like |Link to Comment
  • Amazon - What If Valuation Mattered? [View article]
    Author: do you not mean, "higher lows"? Highers highs and lower lows can be contradictory
    Apr 30 10:56 AM | 0 Likes Like |Link to Comment
  • Trading Raptor Pharmaceuticals' RP 103 FDA Decision [View article]
    Since Cystagon costs 10$k per year/patient, RP-103 att $200k is a 20x increase. Is RP-103 a 20x better drug than Cystagon? Imo no. I think it is a 2x-3x as good drug. Thus, it follows that it's pricing should be $20k-$30k a year
    Apr 29 04:27 PM | 0 Likes Like |Link to Comment
  • Trading Athersys: Risks And Rewards [View article]
    author are you an idiot? I just checked the method you suggested, and it's not public that method either........
    Apr 20 02:10 PM | 0 Likes Like |Link to Comment
  • Trading Athersys: Risks And Rewards [View article]
    i 2nd that as well
    Apr 19 04:12 PM | 1 Like Like |Link to Comment
COMMENTS STATS
226 Comments
57 Likes